Mix2Vial^™ is a plastic, needle-free transfer device for use with Humate-P^®. For nurses, patients, and parents, the Mix2Vial^™ is efficient and convenient, helping to minimize the risk of accidental injury and the time required to prepare Humate-P^®.

Mix2Vial™ Benefits:

Less risk of accidental injury
Less time to prepare product
Simple process encourages independence
Built-in filter
Use with all Luer-Lok^® syringes

View a video showing how to mix Humate-P^® using Mix2Vial^™ Needle-Free Transfer Device.

We encourage you to see the Mix2Vial^™ Needle-Free Transfer Device firsthand. Ask your healthcare professional for a demonstration, or call your local CSL Behring representative to find out about events scheduled across the country where you can see how the Mix2Vial^™ works.

Request a reusable infusion mat to use when mixing Humate-P^®. This colorful instructional mat is designed to be used on your countertop or wherever you infuse. The mat is wipeable, foldable, and convenient for use at home or when you travel.

The Mix2Vial™ Needle-Free Transfer Device is a simple way to mix Humate-P<sup>®</sup>

Luer-Lok^® is a trademark of Becton, Dickinson and Company.

Did you know that you can self-infuse Humate-P at home using the Mix2Vial?
Watch a video on the 6 steps of self-infusion.

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.